CSTL
$25.00-0.70 (-2.72%)
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions.
Recent News
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets
Castle Biosciences is back in focus as some analysts move price targets from the mid $30s to around $52, while at least one fair value view at $48.5 remains unchanged. These shifts are being tied directly to preliminary 2025 revenue disclosures and refreshed 2026 revenue estimates, with differing opinions on how much the new data supports higher targets. As you read on, you will see how these evolving views fit together and what to watch next as the narrative develops. Analyst Price Targets...
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.